This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ProMIS Neurosciences Crecimiento futuro

Future controles de criterios 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for ProMIS Neurosciences.

Información clave

9.3%

Tasa de crecimiento de los beneficios

13.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	36.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	17 Jul 2023

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We're A Little Worried About ProMIS Neurosciences' (TSE:PMN) Cash Burn Rate

Oct 11

Despite Lacking Profits ProMIS Neurosciences (TSE:PMN) Seems To Be On Top Of Its Debt

Jun 23

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

Mar 07

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

Nov 19

Previsiones de crecimiento de beneficios e ingresos

TSX:PMN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	N/A	-18	N/A	N/A	1
12/31/2024	N/A	-14	N/A	N/A	1
12/31/2023	N/A	-17	N/A	N/A	1
3/31/2023	N/A	-21	-16	-16	N/A
12/31/2022	N/A	-18	-17	-17	N/A
9/30/2022	0	-12	-16	-16	N/A
6/30/2022	0	-8	-15	-15	N/A
3/31/2022	N/A	-6	-12	-12	N/A
12/31/2021	N/A	-10	-9	-9	N/A
9/30/2021	N/A	-8	-6	-6	N/A
6/30/2021	N/A	-8	-4	-4	N/A
3/31/2021	0	-9	-3	-3	N/A
12/31/2020	0	-4	-4	-3	N/A
9/30/2020	0	-5	-4	-4	N/A
6/30/2020	0	-5	-4	-4	N/A
3/31/2020	0	-5	-4	-4	N/A
12/31/2019	0	-6	-5	-5	N/A
9/30/2019	0	-7	-6	-6	N/A
6/30/2019	0	-8	-7	-7	N/A
3/31/2019	0	-8	-7	-7	N/A
12/31/2018	0	-7	-6	-6	N/A
9/30/2018	0	-6	-6	-6	N/A
6/30/2018	0	-5	-5	-5	N/A
3/31/2018	0	-5	-5	-5	N/A
12/31/2017	0	-5	-5	-5	N/A
9/30/2017	0	-5	-4	-4	N/A
6/30/2017	0	-4	-3	-3	N/A
3/31/2017	0	-3	-3	-3	N/A
12/31/2016	0	-3	N/A	-2	N/A
9/30/2016	0	-2	N/A	-2	N/A
6/30/2016	0	-2	N/A	-2	N/A
3/31/2016	0	-2	N/A	-2	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-1	N/A	-1	N/A
6/30/2015	0	-2	N/A	-1	N/A
3/31/2015	0	-2	N/A	-1	N/A
12/31/2014	0	-2	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-2	N/A	-2	N/A
3/31/2014	0	-2	N/A	-2	N/A
12/31/2013	0	-2	N/A	-1	N/A
9/30/2013	0	-2	N/A	-1	N/A
6/30/2013	0	-2	N/A	-2	N/A
3/31/2013	0	-2	N/A	-2	N/A
12/31/2012	0	-2	N/A	-2	N/A
9/30/2012	0	-3	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: PMN is forecast to remain unprofitable over the next 3 years.

Beneficios vs. Mercado: PMN is forecast to remain unprofitable over the next 3 years.

Beneficios de alto crecimiento: PMN is forecast to remain unprofitable over the next 3 years.

Ingresos vs. Mercado: Insufficient data to determine if PMN's revenue is forecast to grow faster than the Canadian market.

Ingresos de alto crecimiento: PMN is forecast to have no revenue next year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if PMN's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

ProMIS Neurosciences Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

No longer forecast to breakeven

Recent updates

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

No longer forecast to breakeven

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

We're A Little Worried About ProMIS Neurosciences' (TSE:PMN) Cash Burn Rate

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

Chairman & CEO recently bought CA$64k worth of stock

Despite Lacking Profits ProMIS Neurosciences (TSE:PMN) Seems To Be On Top Of Its Debt

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

Full year 2021 earnings: EPS misses analyst expectations

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

Full year 2020 earnings released: CA$0.02 loss per share (vs CA$0.028 loss in FY 2019)

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

Earnings miss expectations

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

Earnings released

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento